Kimmtrak Tebentafusp tebn 100mcg Injection 1's

KIMMTRAK contains tebentafusp-tebn, a bispecific protein that directs the body's T cells to recognize and attack cancer cells expressing a gp100-derived peptide presented by HLA-A*02:01.

It binds to the gp100 peptide–HLA complex on tumor cells and to CD3 on T cells, bringing the immune cells into contact with the cancer cells and helping trigger an immune response.

Important: KIMMTRAK is a specialized immunotherapy used to treat certain adults with unresectable or metastatic uveal melanoma, a rare cancer originating in the eye. Treatment is restricted to patients who test positive for the HLA-A*02:01 genetic marker. It carries a boxed warning for potentially life-threatening cytokine release syndrome (CRS) and must be administered under specialist medical supervision.

• Unresectable uveal melanoma: Eye melanoma that cannot be removed surgically.
• Metastatic uveal melanoma: Uveal melanoma that has spread to other parts of the body.

It is intended for adults who test positive for HLA-A*02:01. It is not a general treatment for all types of melanoma, and eligibility must be confirmed by the treating oncologist.

• Targeted immune activity: Helps T cells recognize and attack cancer cells carrying the relevant gp100 peptide–HLA complex.
• Cancer control: May slow disease progression in eligible patients.
• Survival benefit: In the pivotal clinical study of metastatic uveal melanoma, patients receiving tebentafusp had longer overall survival than patients receiving the comparator treatments. Individual responses vary.

KIMMTRAK is not a conventional chemotherapy drug; it works by redirecting immune cells toward tumor cells.

KIMMTRAK is administered by a healthcare professional as an intravenous infusion over approximately 15–20 minutes. It must not be self-administered.

The US-approved dose-escalation schedule is:

Treatment day: Recommended dose:

Day 1: 20 micrograms

Day 8: 30 micrograms

Day 15: 68 micrograms

Thereafter, 68 micrograms once weekly

Monitoring is essential: Patients must be monitored for at least 16 hours following each of the first three infusions because CRS can be serious or life-threatening. Subsequent monitoring is determined by the treating team.

The vial contains 100 micrograms in 0.5 mL; this is the vial strength, not the recommended dose for every infusion. Dose preparation and administration must follow the official protocol.

Common:

• Frequently reported adverse reactions include:
• Cytokine release syndrome (CRS)
• Skin rash and itching
• Fever and chills
• Fatigue or weakness
• Nausea and vomiting
• Abdominal pain
• Swelling (oedema)
• Low blood pressure
• Dry skin
• Headache

Laboratory abnormalities can include changes in liver enzymes, creatinine, blood glucose, hemoglobin, lymphocyte count, and phosphate. Regular monitoring is important.

Serious:

• Cytokine release syndrome (CRS)

This can be life-threatening, particularly during the first three infusions. Symptoms may include fever, chills, low blood pressure, dizziness, vomiting, headache, weakness, low oxygen levels, or difficulty breathing.

• Severe allergic or infusion-related reactions

Report breathing difficulty, wheezing, facial or throat swelling, or sudden dizziness immediately.

• Severe skin reactions

A worsening rash, extensive itching, or significant skin swelling may require prompt assessment and treatment.

• Liver injury

Elevated liver enzymes may occur. The oncology team should monitor liver function and assess symptoms such as jaundice, dark urine, or persistent upper abdominal discomfort.

Seek emergency medical care for breathing difficulty, fainting, severe dizziness, confusion, or rapidly worsening symptoms during or after an infusion.

Formal drug-interaction studies with KIMMTRAK are limited. Unlike many oral targeted cancer medicines, it is a protein-based immunotherapy and is not primarily cleared through the usual drug-metabolizing CYP enzyme pathways.

Important precautions include:

• Immunosuppressants and corticosteroids: These may affect immune activity. Corticosteroids may nevertheless be required to manage severe CRS or other treatment complications under medical supervision.
• Other anticancer treatments: Combining KIMMTRAK with other immunotherapies or cancer medicines should be decided by the oncology team.
• Medicines affecting blood pressure: KIMMTRAK may cause hypotension; review antihypertensive medicines and monitor blood pressure.
• All other medicines: Inform the treating team about prescription medicines, over-the-counter products, supplements, and herbal preparations.

Do not start, stop, or change any medicine without medical advice.

• Store unopened vials refrigerated at 2°C–8°C (36°F–46°F).
• Keep the vial in its original carton to protect it from light.
• Do not freeze or shake.
• Follow the product label and institutional procedures for preparation, handling, and disposal.
• The prepared infusion must be used within the time limits specified in the official prescribing information.

KIMMTRAK requires a reliable cold chain during storage and transportation.

• Confirm HLA-A*02:01 positivity before treatment.
• Receive treatment only at a facility equipped to monitor and manage CRS and severe infusion-related reactions.
• Attend all scheduled weekly infusions and follow-up appointments.
• Ensure blood pressure, liver function, and other relevant laboratory parameters are monitored.
• Report fever, chills, dizziness, rash, vomiting, or breathing problems promptly, especially after early doses.
• Do not discontinue or delay treatment without consulting the oncologist.